Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TAK-242
Resatorvid · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Resatorvid 1.2 mg/kg/day | EXPERIMENTAL | - |
| Resatorvid 2.4 mg/kg/day | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Resatorvid | DRUG | Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours. |
| Placebo | DRUG | Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours. |
Inclusion Criteria: * Has clinical evidence of infection defined as the presence of a known or probable source of infection requiring the initiation of parenteral antimicrobial therapy. * Must meet at least 3 of the following 4 criteria for SIRS: * A core temperature greater than 38°C or less th...
Top 3 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| ImmunityBio Inc | IBRX | 2 | PHASE2 | Nogapendekin alfa inbakicept |
| Bayer | BAYRY | 2 | PHASE1 | BAY 3389934 |
Resatorvid was developed as a treatment for severe sepsis in adults. It is a small molecule antiviral and anti-inflammatory agent that was studied in a Phase 3 clinical trial in patients with severe sepsis. The drug has not been approved for commercial use and remains an investigational therapy.
Resatorvid targets TLR4, also known as Toll-like receptor 4. It acts as an inhibitor of this receptor. TLR4 is involved in the innate immune response to bacterial infections, and inhibiting it was intended to reduce the excessive inflammatory response associated with severe sepsis.
Resatorvid was developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor responsible for the clinical development of the drug, including the Phase 3 trial conducted in patients with severe sepsis.
Resatorvid reached Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
Resatorvid was studied in one completed Phase 3 trial, NCT00143611, titled Efficacy and Safety of Resatorvid in Adults With Severe Sepsis. The trial enrolled 277 adults aged 18 and older across the United States, Europe, Japan, Australia, Canada, Israel, New Zealand, and Puerto Rico.
Yes. The Phase 3 trial of Resatorvid, NCT00143611, was randomized, double blind, and placebo controlled. It enrolled 277 adults with severe sepsis and has been completed. The study included participants of all sexes and did not use biomarker selection for enrollment.